Takotsubo Syndrome a Rare Entity in COVID-19: a Systemic Review-Focus on Biomarkers, Imaging, Treatment, and Outcome.

摘要: Takotsubo syndrome(TTS) is attributed to catecholamine surge, which also observed in COVID-19 disease due the cytokine storm. We performed a systematic literature search using PubMed, Embase, and Cochrane Central Register of Controlled Trials retrospectively identify COVID-19-associated TTS case reports evaluated patient-level demographics, laboratory markers clinical attributes, treatment given, outcomes. There are 27 cases reported associated with infection 44.5% were male. Reported median age was 57 years (IQR: 39-65) 62.95 years 50.5-73.5) series individual patients' database, respectively. The time interval from symptom onset diagnosis 6.5 days 1.0-8.0) 6.7 days 4-10) database. LVEF 36% 35-37) 38.15%(IQR: 30-42.5%-[male: 40.33% 33-44.2)] female [37.15% 30-40)] individual-patients' Troponin elevated all patients except one patient. 77.2% had an C-reactive protein and/or D-dimer. Twelve out 22 (54.5%) developed cardiac complication such as cardiogenic-shock, atrial fibrillation, acute heart failure, supraventricular tachycardia, biventricular failure. Nineteen 26 (73.07%) discharged, three hospitalized respiratory distress syndrome needed extracorporeal membrane oxygenation or ongoing maternal age. 4 (14.8%) mortality. no major gender difference development unlike per se. Older group for irrespective cardiovascular comorbidities probably reflects independent risk factor. Patients who higher mortality rate especially if they cardiogenic shock.